Shared Decision-Making in Diabetes Care

被引:0
作者
Shrikant Tamhane
Rene Rodriguez-Gutierrez
Ian Hargraves
Victor M. Montori
机构
[1] Mayo Clinic,Knowledge and Evaluation Research Unit, Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Department of Medicine
来源
Current Diabetes Reports | 2015年 / 15卷
关键词
Shared decision-making; Diabetes; Evidence-based medicine; Decision aids;
D O I
暂无
中图分类号
学科分类号
摘要
Shared decision-making (SDM) is a collaborative process by which patients and clinicians work together in a deliberative dialogue. The purpose of this dialogue is to identify reasonable management options that best fit and addresses the unique situation of the patient. SDM supports the patient-centered translation of research into practice. SDM also helps implement a core principle of evidence-based medicine: evidence is necessary but never sufficient to make a clinical decision, as consideration of patient values and context is also required. SDM conversations build on a partnership between the patient and the clinician, draw on the body of evidence with regard to the different treatment options, and consider options in light of the values, preferences, and context of the patient. SDM is appropriate for diabetes care because diabetes care often requires consideration of management options that differ in ways that matter to patients, such as the way in which they place significant demands on patient’s life and living. In the last decade, SDM has proven feasible and useful for sharing evidence with patients and for involving patients in making decisions with their clinicians. Health care and clinical policies advocate SDM, but these policies have yet to impact diabetes care. In this paper, we describe what SDM is, its known impact on diabetes care, and needed work to implement this patient-centered approach in the care of the millions of patients with diabetes.
引用
收藏
相关论文
共 159 条
[21]  
Guyatt GH(2015)The global impact of non-communicable diseases on healthcare spending and national income: a systematic review Eur J Epidemiol 30 251-13
[22]  
Crawley L(2013)The financial burden from non-communicable diseases in low- and middle-income countries: a literature review Health Res Policy Syst 11 31-203
[23]  
Davidoff F(2006)Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy N Engl J Med 355 2427-9
[24]  
Haynes B(2012)Evaluation of guideline recommendations on oral medications for type 2 diabetes mellitus: a systematic review Ann Intern Med 156 27-7
[25]  
Sackett D(2011)Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations Ann Intern Med 154 602-26
[26]  
Sackett DL(2009)Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 32 193-8
[27]  
Rosenberg WM(2015)Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 38 140-82
[28]  
Gray JA(2015)The relationship of individual comorbid chronic conditions to diabetes care quality BMJ Open Diabetes Res Care 3 e000080-40
[29]  
Richardson PE(2007)Multimorbidity’s many challenges BMJ 334 1016-22
[30]  
Hoffmann TC(2015)Finalizing a measurement framework for the burden of treatment in complex patients with chronic conditions Patient Relat Outcome Meas 6 117-97